Core E, Virology, Proteomics and Microbial Pathogenesis (VPMP), is the main resource provided by the CFAR to support virological investigations of HIV and studies of its co-pathogens, Mycobacterium tuberculosis (MTB) and Hepatitis C Virus (HCV). The Core has been newly configured to provide a wide range of services in support of modern virology research that now includes mass spectrometry, live cell sorting, and proteomics, novel services for the rapid production of recombinant viruses, as well as state-of- the-art biosafety facilities, that include high throughput live cell sort facilities for infectious samples.
The specific aims of the Virology, Proteomics and Microbial Pathogenesis core are: ? Virology: Provide recombinant HIV viruses using novel recombination methods in yeast recently developed by the Arts laboratory to rapidly generate viruses with desired properties. Provide access to a virus repository carrying a collection of over 500 well-characterized primary HIV isolates. Provide training to enhance the use of recombinant HlV-1 strains. ? Proteomics: Operate mass spectrometry, proteomics facilities and provide a systems biology and bioinformatics infrastructure to support a wide range of projects in HIV/AIDS research currently funded by the NIH. Specifically, proteomic services focus on protein abundance measurements, identification of post-translational modifications, structural proteomics analysis, and pathway analysis. Provide training to enhance the use and understanding of role of advanced Proteomics and Bioinformatics technologies in HIV research. ? Microbial Pathogenesis: Provide fully managed, well-equipped, and safe working environments (Biosafety level 2+ and 3) for the study of HIV, virulent MTB, and HCV, including live cell sorting (LCS) facilities for separation of HIV-infected, HCV-infected, and MTB-infected mononuclear cells. Safety monitoring, management, and training will be provide to the entire CFAR including the Uganda Laboratory Core C. Develop and provide quantitative PCR assays to monitor pathogen growth. Train and monitor researchers in Biosafety laboratories, and in the use of PCR methodologies for pathogen detection.
|Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247|
|Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:|
|Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18|
|Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150|
|Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216|
|Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973|
|Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:|
|Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285|
|Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372|
|Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552|
Showing the most recent 10 out of 539 publications